Julie Vincent
YOU?
Author Swipe
View article: FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial
FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial Open
NCT03795311 (clinicaltrials.gov).
View article: Effect of radiochemotherapy on peripheral immune response in glioblastoma
Effect of radiochemotherapy on peripheral immune response in glioblastoma Open
Background Glioblastoma (GBM) is a primary brain tumor with a dismal prognosis, often resistant to immunotherapy and associated with immune suppression. This study aimed to assess the impact of steroids and Stupp-regimen treatment on perip…
View article: FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy
FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy Open
Background Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with platinum chemotherapy was the standard first-line chemotherapeutic regimen until the recent addition of anti-PD-1/PD-L1 antibodies. After disease progres…
View article: SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer
SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer Open
View article: Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma Open
The GemciTest demonstrated that a blood-based RNA signature has the potential to aid in personalized therapy for PDAC, leading to better survival rates for patients receiving a gemcitabine-based first-line treatment.
View article: Data from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Data from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Host immunity controls the development of colorectal cancer, and chemotherapy used to treat colorectal cancer is likely to recruit the host immune system at some level. Athough preclinical studies have argued that colorectal cancer drugs, …
View article: Supplementary Figure 6: mRNA relative expression of genes involved in immunosuppression from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 6: mRNA relative expression of genes involved in immunosuppression from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
gMDSC and mMDSC were cell sorted from four mCRC patient blood. mRNA were extracted and the expression of Entpd1, Nt5e, Pdl1, Pdl2, Indo, Arg1 and Inos was determined using RT-qPCR.
View article: Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis. from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis. from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Flow cytometry gating strategy to identify MDSC subpopulations and granulocytes (1) through SCC-A, Lin- (=CD3, CD20, CD19 and CD56) CD14, CD15, CD33 and HLA-DR labeling (upper panel). For each selected population with CD14 and CD15 labelli…
View article: Data from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Data from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Host immunity controls the development of colorectal cancer, and chemotherapy used to treat colorectal cancer is likely to recruit the host immune system at some level. Athough preclinical studies have argued that colorectal cancer drugs, …
View article: Supplementary Table 2: Human primer sequences used for RT-qPCR analysis from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Table 2: Human primer sequences used for RT-qPCR analysis from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
List of primer used for mRNA relative expression in different myeloid subsets.
View article: Supplementary Figure 4: IFN-γ and IL-17A secretion by CCR6 and CXCR3 expressing CD4 T cells from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 4: IFN-γ and IL-17A secretion by CCR6 and CXCR3 expressing CD4 T cells from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
PBMCs of mCRC patients were stained after PMA/ionomycin/Brefeldin/Monensin stimulation (4 hrs) with anti-CD4, anti-CD45RA, anti-CCR6, anti-CXCR3, anti-IFN-γ and anti-IL-17A antibodies and analyzed by flow cytometry. The expression of IFN-γ…
View article: Supplementary Figure Legends from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure Legends from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Supplementary Figure 1: THelper gating strategy Flow cytometry gating strategy to identify memory CD4 T cell subpopulations through chemokine receptor expression. Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis.…
View article: Supplementary Figure 3: Blood parameters in Healthy Volunteers versus mCRC patients from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 3: Blood parameters in Healthy Volunteers versus mCRC patients from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Whole blood of Healthy volunteers and metastatic colorectal cancer patient (mCRC) was sample on EDTA-K2 tubes (BD Bioscience) and a complete blood count (CBC) was performed in Clinical Biology Unit (Centre George François Leclerc).
View article: Supplementary Figure 5: Blood parameters in mCRC patients, D0 versus D15 from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 5: Blood parameters in mCRC patients, D0 versus D15 from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Whole blood of metastatic colorectal cancer patient (mCRC) was sample before (D0) and after chemotherapy (D15) on EDAT-K2 tubes (BD Bioscience) and a complete blood count (CBC) was performed in Clinical Biology Unit (Centre George François…
View article: Supplementary Figure 1: THelper gating strategy from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 1: THelper gating strategy from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Flow cytometry gating strategy to identify memory CD4 T cell subpopulations through chemokine receptor expression.
View article: Supplementary Table 2: Human primer sequences used for RT-qPCR analysis from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Table 2: Human primer sequences used for RT-qPCR analysis from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
List of primer used for mRNA relative expression in different myeloid subsets.
View article: Supplementary Figure 4: IFN-γ and IL-17A secretion by CCR6 and CXCR3 expressing CD4 T cells from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 4: IFN-γ and IL-17A secretion by CCR6 and CXCR3 expressing CD4 T cells from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
PBMCs of mCRC patients were stained after PMA/ionomycin/Brefeldin/Monensin stimulation (4 hrs) with anti-CD4, anti-CD45RA, anti-CCR6, anti-CXCR3, anti-IFN-γ and anti-IL-17A antibodies and analyzed by flow cytometry. The expression of IFN-γ…
View article: Supplementary Table 1: Patient and Healthy volunteer's characteristics from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Table 1: Patient and Healthy volunteer's characteristics from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Baseline characteristics (Age, Sex, Tumor origin, K-Ras and B-Raf status, number of metastatic sites, LDH, PA and CEA) of metastatic colorectal cancer patients (mCRC) and healthy volunteers.
View article: Supplementary Figure 6: mRNA relative expression of genes involved in immunosuppression from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 6: mRNA relative expression of genes involved in immunosuppression from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
gMDSC and mMDSC were cell sorted from four mCRC patient blood. mRNA were extracted and the expression of Entpd1, Nt5e, Pdl1, Pdl2, Indo, Arg1 and Inos was determined using RT-qPCR.
View article: Supplementary Table 1: Patient and Healthy volunteer's characteristics from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Table 1: Patient and Healthy volunteer's characteristics from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Baseline characteristics (Age, Sex, Tumor origin, K-Ras and B-Raf status, number of metastatic sites, LDH, PA and CEA) of metastatic colorectal cancer patients (mCRC) and healthy volunteers.
View article: Supplementary Figure 5: Blood parameters in mCRC patients, D0 versus D15 from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 5: Blood parameters in mCRC patients, D0 versus D15 from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Whole blood of metastatic colorectal cancer patient (mCRC) was sample before (D0) and after chemotherapy (D15) on EDAT-K2 tubes (BD Bioscience) and a complete blood count (CBC) was performed in Clinical Biology Unit (Centre George François…
View article: Supplementary Figure Legends from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure Legends from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Supplementary Figure 1: THelper gating strategy Flow cytometry gating strategy to identify memory CD4 T cell subpopulations through chemokine receptor expression. Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis.…
View article: Supplementary Figure 1: THelper gating strategy from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 1: THelper gating strategy from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Flow cytometry gating strategy to identify memory CD4 T cell subpopulations through chemokine receptor expression.
View article: Supplementary Figure 3: Blood parameters in Healthy Volunteers versus mCRC patients from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 3: Blood parameters in Healthy Volunteers versus mCRC patients from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Whole blood of Healthy volunteers and metastatic colorectal cancer patient (mCRC) was sample on EDTA-K2 tubes (BD Bioscience) and a complete blood count (CBC) was performed in Clinical Biology Unit (Centre George François Leclerc).
View article: Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis. from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis. from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Open
Flow cytometry gating strategy to identify MDSC subpopulations and granulocytes (1) through SCC-A, Lin- (=CD3, CD20, CD19 and CD56) CD14, CD15, CD33 and HLA-DR labeling (upper panel). For each selected population with CD14 and CD15 labelli…
View article: Supplementary Figure 1 from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
Supplementary Figure 1 from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Open
Supplementary Figure 1 from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
View article: Data from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
Data from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Open
Myeloid-derived suppressor cells (MDSC) accumulate in the spleen and tumor bed during tumor growth. They contribute to the immune tolerance of cancer notably by inhibiting the function of CD8(+) T cells. Thus, their elimination may hamper …
View article: Supplementary Figure Legend from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
Supplementary Figure Legend from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Open
Supplementary Figure Legend from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
View article: Data from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
Data from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Open
Myeloid-derived suppressor cells (MDSC) accumulate in the spleen and tumor bed during tumor growth. They contribute to the immune tolerance of cancer notably by inhibiting the function of CD8(+) T cells. Thus, their elimination may hamper …
View article: Supplementary Figure 1 from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
Supplementary Figure 1 from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Open
Supplementary Figure 1 from 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity